Norges Bank’s Kronos Bio KRON Stock Holding History

Norges Bank’s Portfolio KRON Stock Details KRON Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-15,000	Closed	-$448K	–	2167
2020 Q4	$448K	Buy	+15,000	New	+$471K	﹤0.01%	2085

Other funds holding KRON

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VVA

Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Norges Bank's KRON Position: Q1 2021 in Review

Norges Bank sold out of Kronos Bio (KRON) in Q1 2021, closing a stake of 15,000 shares — an estimated $448K sold.

Norges Bank first reported a position in KRON in Q4 2020 and held it in 1 quarter. The position peaked at $448K in Q4 2020. 71 funds tracked by Wall St. Rank hold KRON as of Q1 2021.

Norges Bank reported no remaining Kronos Bio position as of Q1 2021 after selling out during the quarter.
Norges Bank sold 15,000 Kronos Bio shares in Q1 2021, an estimated $448K.
Norges Bank first reported a position in Kronos Bio in Q4 2020 and held it in 1 quarter.
Norges Bank's Kronos Bio position peaked at $448K in Q4 2020.
71 funds tracked by Wall St. Rank held Kronos Bio as of Q1 2021.

Based on Norges Bank's 13F filing for Q1 2021, filed 7 May 2021.